We have located links that may give you full text access.
English Abstract
Journal Article
[Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
Harefuah 2012 April
INTRODUCTION: Omalizumab is a humanized monoclonal anti-IgE for the treatment of moderate to severe allergic asthma. Although the treatment has been available for several years, there are some concerns about its safety and efficacy.
AIM: To assess the efficacy and safety of Omalizumab in all asthmatic patients who were treated with Omalizumab during at least 3 months in the Pulmonary Department at the Meir Medical Center.
METHODS: Retrospective analysis was conducted for all our asthmatic patients. Demographic and clinical characteristics of the patients were recorded from the computerized system of the Clalit Medical Service. Data collected included the degree of severity of the asthma, steroids usage, rate of asthma exacerbations, hospitalizations before and with Omalizumab treatment, as well as the safety profile.
RESULTS: Forty seven patients were included in the study; 70% were female; mean age was 61 +/- 12 years. Duration of asthma was 25 +/- 17 years. Asthma exacerbations rate decLined from 70.2% to 38.3% (p=0.007). Pulmonary functions improved from 58 +/- 14% FEV1 to 63 +/- 17% (p=0.002). Forty five percent of the patients had no hospitalizations during the Omalizumab treatment; 25% had one hospitalization, 17% two and 13% had 3 or more hospitalizations. No anaphylaxis or malignancies were observed. No serious adverse events were noticed except for 4 patients with injection site pain.
CONCLUSIONS: Data indicates that the high efficacy of add-on Omalizumab in patients with moderate to severe allergic asthma is accompanied by an acceptable safety profile.
AIM: To assess the efficacy and safety of Omalizumab in all asthmatic patients who were treated with Omalizumab during at least 3 months in the Pulmonary Department at the Meir Medical Center.
METHODS: Retrospective analysis was conducted for all our asthmatic patients. Demographic and clinical characteristics of the patients were recorded from the computerized system of the Clalit Medical Service. Data collected included the degree of severity of the asthma, steroids usage, rate of asthma exacerbations, hospitalizations before and with Omalizumab treatment, as well as the safety profile.
RESULTS: Forty seven patients were included in the study; 70% were female; mean age was 61 +/- 12 years. Duration of asthma was 25 +/- 17 years. Asthma exacerbations rate decLined from 70.2% to 38.3% (p=0.007). Pulmonary functions improved from 58 +/- 14% FEV1 to 63 +/- 17% (p=0.002). Forty five percent of the patients had no hospitalizations during the Omalizumab treatment; 25% had one hospitalization, 17% two and 13% had 3 or more hospitalizations. No anaphylaxis or malignancies were observed. No serious adverse events were noticed except for 4 patients with injection site pain.
CONCLUSIONS: Data indicates that the high efficacy of add-on Omalizumab in patients with moderate to severe allergic asthma is accompanied by an acceptable safety profile.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app